Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial)††Disclosure: Drs. Mahaffey, Cohen, Newby, Ferguson, and Califf have received honoria for speaking from sanofi-aventis. Drs. Mahaffey, Ferguson, and Califf have acted as consultants for sanofi-aventis. Drs. Echols, Velazquez, Santos, and Gurfinkel have no financial relationships to disclose.Melvin Echols, Robert M. Califf, Kenneth W. Mahaffey et al.|The American Journal of Cardiology|2006Cited by 21
Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarctionMauricio G. Cohen, Robert M. Califf, Christopher B. Granger et al.|Journal of the American College of Cardiology|1999Cited by 18
CORONARY ARTERY DISEASE AND CARDIOVASCULAR OUTCOMES IN HEART FAILURE: INSIGHTS FROM THE VERICIGUAT GLOBAL STUDY IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIALPaul W. Armstrong, Kevin Anstrom, Javed Butler et al.|Journal of the American College of Cardiology|2021Cited by 0